New review shows a specific HIV drug combo may improve cholesterol and kidney health

People living with HIV have many treatment options, but finding one that protects your heart and kidneys is vital. A new systematic review looked at data from many studies to compare a specific drug combination called bictegravir, emtricitabine, and tenofovir alafenamide against other common regimens. This analysis focused on people who had already taken HIV medication before. The team tracked how these drugs affected blood fats and kidney function over 48 weeks. The results were promising for this specific combination. It showed better changes in total cholesterol and triglycerides compared to the other drugs tested. The review also noted that kidney function markers improved with this new option. Safety was a major part of the analysis. Participants generally had similar levels of side effects and discontinuations as those on other therapies. The drugs were generally well tolerated by the group. While the review did not report specific numbers for every single outcome, the overall direction of the data favored this new combination for heart and kidney health. This information helps doctors and patients choose a safe option for long-term management.